胆汁淤积性瘙痒的发病机制

摘要/Abstract

摘要： 胆汁淤积(cholestasis)是指由于肝内或肝外原因导致胆汁分泌及排泄障碍,不能正常到达十二指肠而反流入血液循环引起的一系列病理生理改变。瘙痒是慢性胆汁淤积性疾病患者中仅次于疲劳的最常见症状。慢性瘙痒可导致注意力不集中、睡眠不足和自主活动。在最严重的情况下,可能会出现自杀念头。恶性肿瘤尤其是消化道肿瘤常引起恶性梗阻性胆汁淤积。在恶性胆道梗阻中,高达45%有瘙痒症状,而在良性梗阻中,只有16%有瘙痒症状。胆汁淤积性瘙痒可广泛出现在全身,也可局限于四肢(主要是手掌和脚底)。本文对胆汁淤积性瘙痒的发病机制进行了系统性的阐述。

李奕卓, 吴成利. 胆汁淤积性瘙痒的发病机制[J]. 肝脏, 2022, 27(9): 1045-1047.

参考文献

[1] Murray-Brown F L. Naltrexone for cholestatic itch: a systematic review. BMJ Support Palliat Care, 2021, 11(2): 217-225.
[2] Langedijk J, Beuers U H, Oude Elferink R P J. Cholestasis-Associated pruritus and its pruritogens. Front Med (Lausanne), 2021, 8:639-674.
[3] Yosipovitch G, Rosen J D, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol, 2018, 142(5): 1375-1390.
[4] Jones E A, Bergasa N V. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology, 1990, 11(5): 884-887.
[5] Golpanian R S, Yosipovitch G, Levy C. Use of butorphanol as treatment for cholestatic itch. Dig Dis Sci, 2021, 66(5): 1693-1699.
[6] Tao K M, Tao Y, Chen C Y, et al. Proteinase-activated receptor 1 contributed to up-regulation of enkephalin in keratinocytes of patients with obstructive jaundice. Anesthesiology, 2014, 121(1): 127-139.
[7] Marzioni M, Alpini G, Saccomanno S, et al. Endogenous opioids modulate the growth of the biliary tree in the course of cholestasis. Gastroenterology, 2006, 130(6): 1831-1847.
[8] Tao K, Zhu J, Wei K, et al. Cannabinoid receptor-2 activation in keratinocytes contributes to elevated peripheral beta-endorphin levels in patients with obstructive jaundice. Anesth Analg, 2021, 133(1): 251-262.
[9] Nelson L, Vergnolle N, D'mello C, et al. Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J Hepatol, 2006, 44(6): 1141-1149.
[10] Dagenais C, Ducharme J, Pollack G M. Uptake and efflux of the peptidic delta-opioid receptor agonist. Neurosci Lett, 2001, 301(3): 155-158.
[11] Wang Z, Jiang C, Yao H, et al. Central opioid receptors mediate morphine-induced itch and chronic itch via disinhibition. Brain, 2021, 144(2): 665-681.
[12] Tubog T D, Harenberg J L, Buszta K, et al. Use of nalbuphine for treatment of neuraxial opioid-induced pruritus: a systematic review and meta-analysis. AANA J, 2019, 87(3): 222-230.
[13] Lieu T, Jayaweera G, Zhao P, et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology, 2014, 147(6): 1417-1428.
[14] Alemi F, Kwon E, Poole D P, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest, 2013, 123(4): 1513-1530.
[15] Meixiong J, Vasavda C, Snyder S H, et al. MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus. Proc Natl Acad Sci USA, 2019, 116(21): 10525-10530.
[16] Cipriani S, Renga B, D'amore C, et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling. PLoS One, 2015, 10(7): e0129866.
[17] Kremer A E, Martens J J, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology, 2010, 139(3): 1008-1018, e1.
[18] Shimizu Y, Morikawa Y, Okudaira S, et al. Potentials of the circulating pruritogenic mediator lysophosphatidic acid in development of allergic skin inflammation in mice: role of blood cell-associated lysophospholipase D activity of autotaxin. Am J Pathol, 2014, 184(5): 1593-1603.
[19] Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem, 2002, 277(42): 39436-39442.
[20] Sun Y, Zhang W, Evans J F, et al. Autotaxin, pruritus and primary biliary cholangitis (PBC). Autoimmun Rev, 2016, 15(8): 795-800.
[21] Domocos D, Selescu T, Ceafalan L C, et al. Role of 5-HT1A and 5-HT3 receptors in serotonergic activation of sensory neurons in relation to itch and pain behavior in the rat. J Neurosci Res, 2020, 98(10): 1999-2017.
[22] Dillon S, Tobias J D. Ondansetron to treat pruritus due to cholestatic jaundice. J Pediatr Pharmacol Ther, 2013, 18(3): 241-246.
[23] 王学龙. 5-HT系统调控大鼠胆汁淤积诱导的抗伤害性及瘙痒机制的研究.苏州大学, 2016.
[24] Smith D D, Rood K M. Intrahepatic cholestasis of pregnancy. Clin Obstet Gynecol, 2020, 63(1): 134-151.
[25] Kremer A E, Oude Elferink R P, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol, 2011, 35(2): 89-97.
[26] Mencarelli A, Fiorucci S. FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med, 2010, 14(1-2): 79-92.
[27] Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med, 2016, 375(7): 631-643.
[28] Festa C, Renga B, D'amore C, et al. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. J Med Chem, 2014, 57(20): 8477-8495.
[29] Bolier R, Oude elferink R P, Beuers U. Advances in pathogenesis and treatment of pruritus. Clin Liver Dis, 2013, 17(2): 319-329.